Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Nerviano Medical Sciences, Italfarmaco Partner on Novel PDC | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Nerviano Medical Sciences, Italfarmaco Partner on Novel PDC

ITF will use NMS’s linker-payload technology to develop a novel PDC product candidate.

By: Anthony Vecchione

Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company, signed a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).

Under the terms of the agreement, ITF will use NMS’s linker-payload technology to develop a novel PDC product candidate. NMS has implemented linker-payload GMP manufacturing and supply at a CDMO referred by NMS. ITF will be responsible for generating the target peptide and all non-clinical, clinical, and commercialization activities related to any resulting proprietary product candidates.

“NMS’s cutting-edge linker-payload technology will allow us to develop new peptide drug conjugates for the treatment of oncology indications with high unmet medical need, leveraging Italfarmaco’s state-of-the-art GMP peptide production capabilities,” said Christian Steinkühler, Italfarmaco Group’s chief scientific officer. “This is an important milestone in our mission to generate a highly diversified pipeline of innovative medicines.”

“We are pleased that ITF, a company with a long-standing heritage both from pharmaceutical and chemical sectors, has selected our linker-payload first platform for developing a truly novel peptide-drug conjugate. This is a significant step to broaden the applicability of our technology,” said Hugues Dolgos, CEO of NMS, and NMS Group.


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics